This inventive strategy demonstrated clear efficacy in multiple models of myeloma, but may also present an opportunity for the treatment of solid tumors which rely on normal CD38-expressing immune cells for tumor cell elimination. This evidence concerns the gene CD38 and plasma cell myeloma.